The study investigates the long-term health consequences of COVID-19 in patients discharged from hospital, focusing on symptoms, pulmonary function, and psychological well-being. The research is based on a cohort of 1733 adult patients who were discharged from Jin Yin-tan Hospital in Wuhan, China, between January 7 and May 29, 2020. The follow-up period was from June 16 to September 3, 2020, with a median follow-up time of 186 days after symptom onset. Key findings include: - **Symptoms**: 68% of patients reported at least one symptom at follow-up, with fatigue or muscle weakness (52%) and sleep difficulties (26%) being the most common. Anxiety or depression was reported by 23% of patients. - **Pulmonary Function**: Patients with more severe illness during hospitalization had higher rates of pulmonary diffusion impairment and abnormal chest imaging. The prevalence of diffusion impairment was 22% for severity scale 3, 29% for scale 4, and 56% for scale 5-6. - **Psychological Well-being**: 23% of patients reported anxiety or depression at follow-up, with a higher prevalence in females. - **Antibody Levels**: Neutralizing antibody seropositivity and median titres were significantly lower at follow-up compared to the acute phase, raising concerns about the risk of reinfection. The study highlights the need for long-term follow-up and intervention for patients with severe COVID-19 to address persistent health issues.The study investigates the long-term health consequences of COVID-19 in patients discharged from hospital, focusing on symptoms, pulmonary function, and psychological well-being. The research is based on a cohort of 1733 adult patients who were discharged from Jin Yin-tan Hospital in Wuhan, China, between January 7 and May 29, 2020. The follow-up period was from June 16 to September 3, 2020, with a median follow-up time of 186 days after symptom onset. Key findings include: - **Symptoms**: 68% of patients reported at least one symptom at follow-up, with fatigue or muscle weakness (52%) and sleep difficulties (26%) being the most common. Anxiety or depression was reported by 23% of patients. - **Pulmonary Function**: Patients with more severe illness during hospitalization had higher rates of pulmonary diffusion impairment and abnormal chest imaging. The prevalence of diffusion impairment was 22% for severity scale 3, 29% for scale 4, and 56% for scale 5-6. - **Psychological Well-being**: 23% of patients reported anxiety or depression at follow-up, with a higher prevalence in females. - **Antibody Levels**: Neutralizing antibody seropositivity and median titres were significantly lower at follow-up compared to the acute phase, raising concerns about the risk of reinfection. The study highlights the need for long-term follow-up and intervention for patients with severe COVID-19 to address persistent health issues.